Stock Performance and Market Context
On 27 Feb 2026, Lupin Ltd. touched Rs.2336, marking its highest price in the past year and surpassing its 52-week low of Rs.1774 by a significant margin. This represents a gain of approximately 31.6% from the low point within the last 12 months. The stock’s performance over the past year has been notably strong, delivering a total return of 22.57%, which comfortably outpaces the Sensex’s 9.66% gain over the same period.
Despite the broader market’s subdued tone, with the Sensex falling 371.40 points (-0.49%) to 81,849.08 after a flat opening, Lupin’s shares have demonstrated resilience. The stock traded within a narrow intraday range of Rs.21 today and showed a minor day decline of -0.33%, remaining largely in line with its sector peers.
Technically, Lupin is trading above all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — signalling a strong upward trend. This technical strength is particularly notable given that the Sensex itself is trading below its 50-day moving average, although the 50DMA remains above the 200DMA, indicating a mixed but cautiously optimistic market backdrop.
Our current monthly pick, this Mid Cap from Automobile Two & Three Wheelers, survived rigorous evaluation against dozens of contenders. See why experts are backing this one!
- - Rigorous evaluation cleared
- - Expert-backed selection
- - Mid Cap conviction pick
Financial Strength and Growth Metrics
Lupin’s recent price surge is underpinned by solid financial fundamentals. The company boasts a low average Debt to Equity ratio of 0.10 times, reflecting a conservative capital structure that supports sustainable growth. Net sales have expanded at an annualised rate of 11.42%, while operating profit margins stand robustly at 33.60%, indicating efficient cost management and strong operational leverage.
Profit before tax excluding other income (PBT less OI) for the latest quarter reached Rs.1,833.91 crores, marking a substantial 43.6% increase compared to the previous four-quarter average. Net sales for the quarter hit a record Rs.7,167.52 crores, further reinforcing the company’s growth trajectory.
Return on Capital Employed (ROCE) for the half-year period is at a high of 22.22%, while Return on Equity (ROE) stands at 22%, highlighting Lupin’s ability to generate attractive returns for shareholders. The company’s valuation metrics remain compelling, with a Price to Book Value ratio of 5.4, trading at a discount relative to its peers’ historical averages.
Institutional investors hold a significant 47.08% stake in Lupin, reflecting confidence from entities with extensive analytical resources and a long-term perspective on fundamentals.
Consistent Performance and Market Recognition
Over the past three years, Lupin has consistently outperformed the BSE500 index annually, demonstrating steady returns and resilience in varying market conditions. The company’s profits have surged by 73.5% over the last year, contributing to a low PEG ratio of 0.3, which suggests the stock is reasonably valued relative to its earnings growth.
MarketsMojo assigns Lupin a Mojo Score of 78.0 with a current Mojo Grade of Buy, upgraded from Strong Buy on 16 Feb 2026. This places Lupin among the top 1% of over 4,000 stocks rated by the platform, underscoring its strong fundamentals and market standing.
Get the full story on Lupin Ltd.! Our detailed research dives into fundamentals, sector comparison, technical analysis, and valuations for this Pharmaceuticals & Biotechnology mid-cap. Make informed decisions!
- - Full research story
- - Sector comparison done
- - Informed decision support
Recent Trading Activity and Momentum
After four consecutive days of gains, Lupin’s stock price experienced a slight pullback today, reflecting a natural consolidation phase following the recent rally. The narrow trading range of Rs.21 suggests limited volatility, which often precedes further directional moves once the consolidation resolves.
The stock’s ability to maintain levels above all major moving averages indicates sustained buying interest and a positive technical setup. This momentum is particularly noteworthy given the broader market’s cautious stance, with the Sensex currently below its 50-day moving average.
Overall, Lupin Ltd.’s achievement of a new 52-week high at Rs.2336 marks a significant milestone that encapsulates the company’s strong financial health, consistent growth, and favourable market positioning within the Pharmaceuticals & Biotechnology sector.
Summary
Lupin Ltd.’s recent price peak at Rs.2336 highlights a year-long upward trajectory supported by robust earnings growth, attractive valuation metrics, and strong institutional backing. Despite a modest intraday decline today, the stock’s technical and fundamental indicators remain positive, reflecting a well-established momentum in a sector that continues to demonstrate resilience. The company’s consistent outperformance relative to the Sensex and BSE500 indices further cements its status as a key player in the mid-cap pharmaceutical space.
Only Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Start Today
